Voltari Corp. (VLTC) soared 144.86% to $8.57 on Tuesday's market activity, with a total volume of 21,267,881 shares traded during the day, a huge increase in activity versus its average volume (3m) of 285,948. There appears to be no relevant information from today that may explain the rally.
The billionaire and activist investor Carl C. Icahn recently disclosed in a regulatory filing ( 13F-HR ) with the Securities and Exchange Commission (SEC) a 52.3% stake (4,739,620 shares) in VLTC.
Shares of VLTC continued the upward direction after the closing bell and climbed more than 9% in the extended session
VLTC is a digital advertising company dedicated to helping companies get the most out of their marketing budgets and the lifetime value of their customers
KaloBios Pharmaceuticals, Inc. (KBIO)'s stock closed $18.40, down $21.10 (or -53.42%), and 6,323,022 of its shares exchanged hands on Tuesday.
According to an SEC filing ( 8-K ), the NASDAQ Stock Market notified KBIO, by letter dated November 17, 2015, that the Company is not currently in compliance with Nasdaq’s continued listing requirement set forth in Rule 5250(c)(1) of the Nasdaq Listing Rules, due to its failure to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2015 with the Securities and Exchange Commission
KBIO recently said that an investor group led by Martin Shkreli, the Founder and Chief Executive Officer of Turing Pharmaceuticals AG, acquired 70% of its outstanding shares. The company officially named Martin Shkreli its new CEO and Chairman of the Board and new members have been elected to the Board of Directors.
According to KBIO, it has received a commitment from Martin Shkreli and other investors for an equity investment of at least $3.0 million. They also have committed to a $10 million equity financing facility, subject to applicable shareholder approval. The company has approximately $5 million in cash
KBIO is a monoclonal antibody company focused on developing innovative therapies to benefit patients with diseases of unmet medical need, with a focus on oncology. It has focused on advancing lenzilumab, an anti-GM-CSF mAb that KaloBios is evaluating in oncology indications where GM-CSF may play a key role, such as chronic myelomonocytic leukemia (CMML). The IND for lenzilumab in CMML, an orphan oncology indication, has been cleared by the FDA
Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWEWorld Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at www.crweworld.com/finance_disclaimer